Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' request for confidential biological samples.
This rejection became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman later stated that the US was seeking health data for research and profit while was not willing to share the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more negotiations to find a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a court halted a similar deal with the US following concerns were raised about the safety of Kenyans' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, representing over $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the final treatments would be available to our population should a future disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were upending systems previously established through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is designed to guarantee that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration could be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but recommended that talks should continue given that a large portion of the country's HIV programmes relied on external financing.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The situation highlights the complex debate between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.